NCT01220453已完成不适用
Compliance and Efficacy in the Use of PICOPREP® for Bowel Cleansing
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 2,165
- 试验地点
- 3
- 主要终点
- Documentation of the use of PICOPREP® in every day practice
研究概览
简要总结
The present trial is aimed to document efficacy (bowel cleanliness), acceptance and tolerability as well as patient comfort in the use of the new bowel cleansing product PICOPREP® in every day practice. In particular, it should be evaluated, whether bowel cleanliness, acceptance, tolerability and patient comfort are affected by specific practice procedures, changes in dose etc.
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients receiving PICOPREP® for bowel evacuation prior to endoscopy or surgery
- •Patients who have been informed about the NIS and have given their written consent for participation
排除标准
- •Patients in which prescription of PICOPREP® is contraindicated
结局指标
主要结局
Documentation of the use of PICOPREP® in every day practice
时间窗: 2 days
Will evaluate efficacy (bowel cleanliness), compliance, acceptance, tolerability and patient comfort
次要结局
- Documentation of patient satisfaction after bowel cleansing(2 days)
- Documentation of examiner satisfaction after colonoscopy(2 days)
- Identification of patient groups in which bowel cleansing is more difficult due to concomitant diseases or other conditions (risk groups)(2 days)
- Tolerability: frequency and severity of adverse events(2 days)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
不适用
MOWOOT Device Treatment for Adults With Chronic ConstipationConstipation - FunctionalConstipation-predominant Irritable Bowel SyndromeConstipation Chronic IdiopathicConstipationNeurogenic ConstipationNCT04666155usMIMA S.L.86
已完成
1 期
Study to Assess PK, Safety and Tolerability in Healthy SubjectsAcute Ischemic StrokeNCT06380699Changzhou Qianhong Bio-pharma Co., Ltd.56
终止
2 期
GSK2251052 in the Treatment of Complicated Intra-abdominal InfectionsInfections, IntestinalNCT01381562GlaxoSmithKline15
Unknown
1 期
Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast CancerChemotherapy-induced NeutropeniaNCT02725606Jiangsu T-Mab Biopharma Co.,Ltd30
已完成
1 期
Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic InsufficiencySafety, Tolerability, and PK of NBI-98854 in Hepatically Impaired SubjectsNCT01916993Neurocrine Biosciences24